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Xtreme Everest 2 (XE2) was part of an ongoing programme of field, laboratory and clinical research focused on
human responses to hypoxaemia that was conducted by the Caudwell Xtreme Everest Hypoxia Research
Consortium. The aim of XE2 was to characterise acclimatisation to environmental hypoxia during a standardised
ascent to high altitude in order to identify biomarkers of adaptation and maladaptation. Ultimately, this may lead to
novel diagnostic and treatment strategies for the pathophysiological hypoxaemia and cellular hypoxia observed in
critically ill patients. XE2 was unique in comparing participants drawn from two distinct populations: native
ancestral high-altitude dwellers (Sherpas) and native lowlanders. Experiments to study the microcirculation,
mitochondrial function and the effect that nitric oxide metabolism may exert upon them were focal to the
scientific profile. In addition, the genetic and epigenetic (methylation and histone modification) basis of observed
differences in phenotype was explored. The biological samples and phenotypic metadata already collected during
XE2 will be analysed as an independent study. Data generated will also contribute to (and be compared with) the
bioresource obtained from our previous observational high-altitude study, Caudwell Xtreme Everest (2007).
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The study of human adaptation to high altitude has a
long history [1]. We have proposed that data obtained
from individuals at high altitude may increase our under-
standing of the pathophysiological effects of hypoxaemia
in patients at sea level [2]. Tissue hypoxia secondary to
hypoxaemia affects many patients admitted to intensive
care units and may contribute to organ failure and eventu-
ally death. Our understanding of how tissues adapt to a
lack of oxygen during disease is somewhat limited, and
inter-individual variation in the response to hypoxaemia is
marked. Due to the heterogeneous nature of critically ill
patients, it is often difficult to elucidate a clear signal be-
cause of the high level of background pathophysiological
noise; such that complex physiological studies in this group
are limited in the conclusions they can draw. Being able to* Correspondence: daniel.martin@ucl.ac.uk
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reproduction in any medium, provided the ortarget specific mechanisms in the critically ill may be
facilitated by preliminary studies in healthy volunteers
ascending to altitude, in which a graded exposure to the
environment hypoxia during ascent creates a paradigm
for pathological hypoxaemia. Comparison of metabolic
and physiological signals in ascending volunteers will
yield information that other models, such as animal and
cell line varieties, cannot generate. Systematic and com-
prehensive investigation of human adaptation to high
altitude therefore provides a robust approach to driving
clinical research in critically ill patients.
In 2007, the University College London Centre for Alti-
tude Space and Extreme Environment (CASE) Medicine
conducted the largest comprehensive prospective observa-
tional study to be performed at altitude: Caudwell Xtreme
Everest (CXE) [3-5]. This study aimed to explore inter-
individual differences in the response to hypobaric hyp-
oxia. In particular, we hypothesized that (1) mechanisms
distinct from those related to global oxygen transport play
an important role in determining performance at high alti-
tude (e.g. metabolic efficiency and microcirculatory bloodLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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substantial proportion of intra-individual variation in
environmentally induced phenotypes (gene-environment
interactions). Results from CXE included novel findings in
relation to microcirculatory blood flow [6,7], mitochon-
drial biology [8-10] and plasma nitrogen oxides [11].
These data led in turn to the core hypotheses for
Xtreme Everest 2 (XE2). In XE2, the function of the
microcirculation, mitochondria and nitric oxide metab-
olism were explored in two different population cohorts:
lowland residents (primarily from the UK) and Sherpas.
An important addition to our previous work has been
the study of epigenetic profiles in all participants.
Data from CXE suggest that in lowlanders, there is
significant inter-individual variability in changes in nitric
oxide biology during ascent to high altitude [11]. Sub-
group analysis of volunteers ascending to 5,300 m sug-
gested higher erythropoietin, nitrate and cGMP levels at
only 3,500 m in participants with considerable extreme
altitude experience compared to those without [11].
Whilst this might simply be the result of self-selection,
it may alternatively represent evidence of epigenetic im-
printing from previous high altitude exposure. Epigen-
etic change, the ability to influence genetic transcription
and translation through environmental stimuli, may
provide a means of identifying candidate biochemical
markers of successful adaptation to high altitude and
thereby lead to viable pharmacological interventions
that may benefit hypoxaemic patients. A pilot study of
identical twins was therefore included as a supplemen-
tary component to the project in order to assess the
methodological feasibility of future epigenetic research
at high altitude.
Xtreme Everest 2
It is possible that Sherpas have additional phenotypic
advantages that are not evident even in high-performing
lowland individuals at altitude. Thus, studying them in
comparison to a cohort of lowland volunteers may identify
traits that are difficult to tease out when looking only at
lowland participants. As direct descendants of highland
Tibetans who may have dwelt at an altitude of over
4,000 m for the past 20,000 years, the Sherpas of Nepal
display exceptional phenotypic adaptation to this envir-
onment. The remote location of the Tibetan plateau
also means that gene flow from other populations is
likely to be minimal. Famed for scaling the Himalayan
Giants whilst supporting lowland mountaineers, Sherpas
demonstrate a high degree of physical resilience to
hypoxia carrying heavy loads with apparently minimal
effort. Whilst genetic inheritance and natural selection
are likely to have led to traits that favour survival at
high altitude, the physiological basis underlying their
performance remains elusive. Of note, they have notbeen shown to demonstrate augmented systemic oxygen
delivery, in contrast to what is commonly seen in low-
land elite athletes at sea level. Strikingly, when com-
pared to other resident high-altitude populations who
have inhabited such heights for shorter periods of time
(Andeans and Ethiopians), Tibetans demonstrate the
lowest haemoglobin concentration [12,13]. The appar-
ent lack of importance of systemic oxygen delivery in
Tibetans/Sherpas suggests that factors in the peripheral
compartment of the oxygen cascade may be of import-
ance. Furthermore, even on descent to a lower altitude,
Tibetans continue to demonstrate lower aerobic energy
expenditure (greater economy of locomotion) during
exercise than control participants [14]. Specifically, the
‘microcirculatory-mitochondrial unit’ may be the site of
beneficial adaptations in Sherpas. Preliminary data sug-
gest that peripheral blood flow is markedly increased in
highland Tibetans compared to lowland populations and
that nitric oxide metabolism may play a role in this [15].
The XE2 study design shared a core dataset and ascent
profile with CXE [5] but added more detailed character-
isation of key pathways (microcirculatory blood flow,
cellular respirometry, epigenetic change) and the com-
parison of different populations. Baseline measurements
were obtained in London (50 m) for the lowlander par-
ticipants and in Kathmandu, Nepal (1,300 m) for Sherpa
participants. During March and April 2013, all partici-
pants ascended to the base camp of Mount Everest
(5,300 m) in groups of up to 14, on an identical ascent
profile to each other and, importantly, to the partici-
pants studied in CXE. This strategy ensured that the
physiological challenge was matched for all participants
and that differences detected between participants would
be attributable to their individual phenotype, rather than
variation in the magnitude or duration of exposure to
hypobaric hypoxia. Data were obtained in dedicated
laboratory facilities at 3,500 m (Namche Bazaar) and
5,300 m (Everest Base Camp) on ascent, and in the major-
ity of participants at 1,300 m (Kathmandu) on descent.
The conduct of XE2 would not have been possible without
close collaboration with the Nepal Health Research
Council and Nepali collaborators. They supported us in
the preparation of ethical and research governance docu-
mentation, the recruitment and consenting of Sherpas, and
subsequently helped with translation in the laboratories.
Detailed phenotypic characterisation included mea-
surements of microcirculatory blood flow and tissue
oxygenation by forearm plethysmography, near-infrared
spectroscopy, tissue laser Doppler and side-stream
darkfield imaging of the sublingual microcirculation.
Mitochondrial function was studied with real-time cel-
lular respiration measurements in fresh skeletal muscle
samples, as well as metabolomic, proteomic and lipidomic
screening of plasma, skeletal muscle and urine samples.
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compartments including plasma, urine, exhaled breath
and saliva. These data will be combined with a core
physiological dataset including daily physiological dairy
incorporating simple cardiorespiratory variables and
symptom scores (e.g. Lake Louise Score) [16] and meas-
urement of oxygen uptake, metabolic efficiency and oxy-
gen kinetics at each laboratory. Finally, we characterised
the epigenetic profiles of all participants to explore the
interaction between genetics, epigenetics and environment
on observed phenotypes. All physiological measurement
devices were tested for robustness and validity during
hypobaric chamber and field testing prior to XE2. The
data collection phase of XE2 has now been completed and
analysis of these data been commenced.Discussion
Hypoxaemia is commonplace amongst critically ill pa-
tients yet optimal management strategies remain un-
certain. Mechanisms that lead to beneficial adaptation,
as opposed to maladaptation, need to be identified in
order to develop individualised treatment strategies.
The current standard response to hypoxaemia in critic-
ally ill patients is to aim for at least normal arterial
oxygenation (and therefore, frequently supra-normal
values are achieved); however, this may not be benefi-
cial and in certain circumstances, may be injurious
[17]. Whilst some augmentation of systemic oxygen
delivery forms an important component of acclimatisa-
tion to high altitude, it fails to explain the marked ob-
served differences in performance between individuals
in this environment [18]. Similarly, there is little evidence
to support the maintenance of normoxaemia in critically
ill patients as a beneficial therapy [19].
Identifying cellular and metabolic differences between
lowland individuals and those adapted over centuries to
the hypoxia of high altitude may identify beneficial
mechanisms of adaptation for subsequent evaluation in
the clinical setting. Sherpa physiology may reveal novel
target pathways that are amenable to pharmacological
manipulation in the critically ill, such as the nitrate-
nitrite-nitric oxide axis. Attempting to mimic the most
effective human hypoxia-tolerant phenotype could pro-
vide new directions in critical care medicine.
The model of studying healthy volunteers ascending
to altitude for the purpose of gaining insight into
hypoxaemic patients is not without limitations. It is
possible that mechanisms elicited at altitude may differ
from those seen in pathology, environment factors other
than hypoxia may confound data obtained in extreme
conditions and differing levels of fitness may influence
responses. However, comprehensive phenotype-genotype
analysis in large groups of healthy volunteers exposed toan identical, graded hypoxic stimulus may unveil other-
wise concealed mechanisms of importance [2,20].
In keeping with our core mission, the aim of XE2 is to
create a large-scale biobank of samples linked to a
phenotype database. This will be used to identify adaptive
mechanisms and drive a translational research agenda.
The consistency of data collection across the research ex-
peditions run by the Caudwell Xtreme Everest Hypoxia
Research Consortium has resulted in a unique bioresource
for the study of human adaptation to hypoxia. Biomarkers
and metabolic pathways can be exploited for patient bene-
fit in an ongoing manner, and the resource can be interro-
gated repeatedly as new techniques evolve.
Conclusions
The unique physiology of the Sherpa people may hold
the key that unlocks the secret of successful hypoxic
adaptation. The bioresource developed from XE2 (and
CXE) provides a unique opportunity to explore human
hypoxic adaptation and thereby drive improvements in
the management of hypoxaemic critically ill patients in
the years to come.
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